A phase III, randomized, open label, multicenter, controlled trial of
niraparib versus physician’s choice in previously-treated, HER2
negative, germline BRCA mutation-positive breast cancer
patients.

    Study Chair
    Dr. Marco Colleoni, EIO Milano, Italy, Nick Turner

    Statistician
    Jan Bogaerts

    Lead Trial Coordinator
    Holly Shaw

    Trial Coordinator
    Poonam Jani 

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


    Date of Activation
    April 1, 2014

    Targeted Accrual
    306

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login